KA2237

· Karus Therapeutics Limited

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for KA2237, covering 2019-02-06 to 2019-02-06. Get the full timeline:

Most recent: Clinical Trial Update: The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110β/δ Inhibitor) In B Cell Lymphoma [Phase 1]

See pricing